Active substanceBetamethasoneBetamethasone
Similar drugsTo uncover
  • Acriderm®
    ointment externally 
    AKRIKHIN HFK, JSC     Russia
  • Acriderm®
    cream externally 
    AKRIKHIN HFK, JSC     Russia
  • Beloderm®
    cream externally 
  • Beloderm®
    ointment externally 
  • Beloderm® Express
    spray externally 
  • Betamethasone
    cream externally 
    VERTEKS, AO     Russia
  • Betamethasone
    ointment externally 
    VERTEKS, AO     Russia
  • Betliben
    cream externally 
  • Betliben
    ointment externally 
  • Diprospan®
    suspension for injections 
    Schering-Plau S.A.     France
  • Diprospan®
    suspension for injections 
  • Flosteron®
    suspension for injections 
  • Celestoderm-B
    ointment externally 
    BAYER, AO     Russia
  • Celestoderm-B
    cream externally 
    BAYER, AO     Russia
  • Dosage form: & nbspointment for external use
    Composition:

    100 g of ointment contains:

    active substance: betamethasone dipropionate in terms of 100% substance 0.064 g, equivalent to 0.05 g of betamethasone;

    Excipients: propyl parahydroxybenzoate 0.05 g, liquid paraffin (vaseline oil) 4 g, isopropyl myristate 1 g, vaseline up to 100 g.

    Description:

    Translucent ointment from white to white with a yellowish hue of color.

    Pharmacotherapeutic group:Glucocorticosteroid for topical application
    ATX: & nbsp

    H.02.A.B.01   Betamethasone

    Pharmacodynamics:

    Acriderm® is a glucocorticosteroid for external use. Has anti-inflammatory, antiallergic, antiexudative, vasoconstrictive, antipruritic and antiproliferative action. It inhibits the accumulation of leukocytes, the release of lysosomal enzymes and proinflammatory mediators in the inflammatory focus, inhibits phagocytosis, reduces vascular-tissue permeability, prevents the formation of inflammatory edema

    When applied to the skin surface, the drug has a quick and powerful effect in the inflammation focus, reducing the severity of objective symptoms (erythema, edema, lichenification) and subjective sensations (itching, irritation, pain).

    Pharmacokinetics:

    When the drug is applied in therapeutic doses, the transdermal absorption of the active substance into the blood is very low. The use of occlusive dressings, inflammation and skin diseases increase the transdermal absorption of betamethasone, which can lead to an increased risk of systemic side effects.

    Indications:

    Diseases of the skin, amenable to glucocorticosteroid therapy:

    - atopic dermatitis;

    - allergic contact dermatitis;

    - eczema (various forms);

    - contact dermatitis (including professional) and other non-allergic dermatitis (including sun and radiation dermatitis);

    - reactions to insect bites;

    - psoriasis;

    - bullous dermatoses;

    - discoid lupus erythematosus;

    - red flat lichen;

    - exudative erythema multiforme;

    - itching of various etiologies.

    Contraindications:

    Hypersensitivity to betamethasone or other components of the drug.

    Tuberculosis of the skin, cutaneous manifestations of syphilis, bacterial, fungal, viral (chickenpox, herpes simplex) skin diseases, skin post-vaccination reactions, open wounds, trophic ulcers of the shin, rosacea, acne vulgaris, skin cancer, nevus, atheroma, melanoma, hemangioma, xanthoma , sarcoma; lactation period and children under 1 year.

    Carefully:

    With prolonged use or application on large surfaces: cataract, diabetes, glaucoma, tuberculosis.

    Pregnancy and lactation:

    The safety of external use of glucocorticosteroids in pregnant women is not established; The prescription of drugs of this group during pregnancy is justified only if the potential benefit to the mother exceeds the possible risk to the fetus.During pregnancy, drugs of this group should not be used in high doses or for a long time.

    If it is necessary to use the drug during lactation it is recommended to stop breastfeeding.

    Dosing and Administration:

    Outwardly. Acriderm® ointment is applied a thin layer on the affected area of ​​the skin 2 times a day - in the morning and in the evening, gently rubbing. On areas with denser skin (for example, elbows, palms and feet) and also places from which the preparation is easily erased, Acriderm® ointment can be applied more often.

    The duration of treatment depends on the effectiveness and tolerability of therapy and is usually not more than 4 weeks. During the year, repeated therapy is possible.

    If clinical improvement does not occur, it is necessary to clarify the diagnosis.

    In children and patients with skin lesions, treatment should not exceed 5 days.

    Side effects:

    As a rule, it has a weak character.

    With external application of glucocorticosteroids, skin itching, burning, irritation, dry skin, folliculitis, hypertrichosis, striae, acne-like eruptions ("steroid" acne), hypopigmentation, perioral dermatitis, allergic contact dermatitis can be observed.

    With prolonged use, as well as the use of occlusive dressings - skin maceration, secondary infection, skin atrophy, local hirsutism, telangiectasia, sweating, purpura.

    When applied to extensive body surfaces, mainly in children, there may be systemic side effects of glucocorticosteroids (hyperglycemia, glucosuria, reversible suppression of adrenal cortex function, manifestation of Isenko-Cushing syndrome).

    If there are any side effects not described in the instructions, you should consult your doctor.

    Overdose:

    Acute overdose is unlikely, however, in case of excessive or prolonged use of the drug, chronic overdose is possible, accompanied by signs of hypercorticism: hyperglycemia, glucosuria, reversible suppression of adrenal cortex function, manifestation of Itenko-Cushing syndrome

    Treatment: it is recommended that the drug be phased out and, if necessary, symptomatic treatment should be performed.

    Interaction:

    Interactions of the drug with other drugs have not been identified.

    Special instructions:

    It is not recommended long-term external application of the drug on the face skin, since it is possible to develop rosacea,perioral dermatitis and acne. The course of treatment should not exceed 5 days.

    Akriderm® ointment is not intended for use in ophthalmology. Avoid contact with eyes. If the product gets on the mucous membranes of the eye, cataracts, glaucoma, fungal infections of the eye and the exacerbation of herpetic infection are possible.

    With long-term treatment, when applying the drug on the vast surface of the skin, as well as in the armpits and inguinal folds, when using occlusive dressings, diapers, systemic absorption of glucocorticosteroids is possible.

    Children from 1 year of the drug is prescribed only for strict indications and under medical supervision, as it is possible to develop systemic side effects associated with betamethasone.

    When applying the drug on large surfaces and / or under the occlusive dressing, it is possible to suppress the function of the hypothalamic-pituitary-adrenal system and the development of symptoms of hypercorticism, a decrease in the excretion of growth hormone, an increase in intracranial pressure can be observed.

    When using ointment in children from 1 year and older, it is necessary to limit the total duration of treatment and exclude activities,leading to increased resorption and absorption (warming, fixing and occlusive dressings, diapers).

    Effect on the ability to drive transp. cf. and fur:

    Does not affect.

    Form release / dosage:

    Ointment for external use, 0.05%.

    Packaging:

    For 15 or 30 g in an aluminum tube.

    Each tube together with instructions for use in a pack of cardboard.

    Storage conditions:

    At a temperature of 15 to 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    4 years.

    Do not use after the expiration date.

    Terms of leave from pharmacies:Without recipe
    Registration number:LS-002317
    Date of registration:11.09.2012 / 12.08.2016
    Expiration Date:Unlimited
    The owner of the registration certificate:AKRIKHIN HFK, JSC AKRIKHIN HFK, JSC Russia
    Manufacturer: & nbsp
    Representation: & nbspAKRIKHIN OJSC AKRIKHIN OJSC Russia
    Information update date: & nbsp03.07.2017
    Illustrated instructions
      Instructions
      Up